Ohio State Navbar

People

Amy Lovett-Racke, PhD


460 W 12th Ave
Columbus, OH 43210

Phone: (614) 688-5647

Email: lovett-racke.1@osu.edu

 

Current OSU Appointments

Associate Professor, SBS-Microbial Infectn/Immunity

Associate Professor, SBS-Neuroscience

 

Chapters in Books

Arredondo LR, Lovett-Racke AE and Racke MK. "Experimental Autoimmune Encephalomyelitis." In Multiple Sclerosis: Immunology, Pathology and Pathophysiology. Edited by RM Herndon. 79-103. New York: Demos Medical Publishing, Inc, January 2003.

Lovett-Racke AE and Racke MK. "The Role of Growth Factors in Experimental Autoimmune Encephalomyelitis." In Experimental Models of Multiple Sclerosis. Edited by E Lavi and CS Constantinescu. 343-361. New York: Springer Science Business Media, Inc, January 2005.

Racke MK, Ratts RB, Stuart RW, Deng C and Lovett-Racke AE. "The Role of Costimulation in Experimental Autoimmune Encephalomyelitis." In Experimental Models of Multiple Sclerosis. Edited by E Lavi and CS Constantinescu. 471-490. New York: Springer Science Business Media, Inc, January 2005.

Lovett-Racke AE, Gocke AR and Cravens PD. "The Basics of Cellular and Molecular Immunology." In Neuroimmunology in Clinical Practice. Edited by B Kalman and TH Brannagan. -. Hoboken, NJ: Wiley Blackwell Publishing, January 2007.

Lovett-Racke AE. "Therapeutic Potential of Small Interfering RNA for Brain Diseases." In Therapeutic Ribonucleic Acids in Brain Tumors. Edited by VA Erdmann, G Reifenberger and J Barciszewski. 275-296. New York, NY: Springer, January 2009.

 

Degrees

1987 B.S., Texas A&M University

1993 Ph.D., The University of Texas Health Science Center at Houston

 

Editorial Activities

2004 Journal of Leukocyte Biology
2005 Acta Pharmacologica Sinica
2005 - 2009 Journal of Neuroimmunology
2007 - present Arthritis and Rheumatism
2007 Proceedings of the National Academy of Science
2008 - present PPAR Research
2008 - present Journal of Immunology
2008 Journal of Neuroimmunology
2009 - present Brain, Behavior and Immunity
2010 - present Journal of Neuroimmunology
 

Honors

1993 - 1995 Intramural Research Training Award. National Institutes of Neurological Disorders and Stroke.
1995 - 1997 Lucille P. Markey Special Emphasis Pathway in Human Pathobiology. Lucille P. Markey Foundation.
2004 - 2009 Harry Weaver Neuroscience Scholar. National Multiple Sclerosis Society.
 

Journal Articles

Fermin CD, Lovett AE, Igarashi M and Dunner K. "Immunohistochemistry and histochemistry of the inner ear gelatinous membranes and statoconia of the chick (Gallus domesticus).." Acta Anatomica. Vol. 138, no. 1. (January 1990.): 75-83.

Wolinsky JS, McCarthy M, Allen-Canady O, Moore WT, Jin R, Cao SN, Lovett-AE and Simmons D. "Monoclonal antibody-defined map of expressed rubella virus protein domains." Journal of Virology. Vol. 65, (January 1991.): 3986-3994.

Wolinsky JS, Sukholutsky E, Moore WT, Lovett AE, McCarthy M and Adame B. "An antibody and synthetic peptide defined rubella virus E1 glycoprotein neutralization domain." Journal of Virology. Vol. 67, (January 1993.): 961-968.

Lovett AE, McCarthy M and Wolinsky JS. "Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides.." The Journal of General Virology. Vol. 74 ( Pt 3), (January 1993.): 445-452.

Lovett AE, Hahn CS, Rice CM, Frey TK, Wolinsky JS. "Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes." Journal of Virology. Vol. 67, no. 10. (January 1993.): 5849-5858.

McCarthy M, Lovett AE, Kerman RH, Overstreet A and Wolinsky JS. "Immunodominant T cell epitopes of rubella virus structural proteins and synthetic peptides." Journal of Virology. Vol. 67, (January 1993.): 673-681.

Lovett-Racke AE, Martin R, McFarland HF, Racke MK and Utz, U. "Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis.." Journal of Neuroimmunology. Vol. 78, no. 1-2. (January 1997.): 162-71.

Racke MK and Lovett-Racke AE. "Bystander suppression in experimental autoimmune encephalomyelitis: where and how does it occur?." Research in Immunology. Vol. 149, (January 1998.): 820-827.

Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH and Racke MK. "Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.." Journal of Clinical Investigation. Vol. 101, no. 4. (January 1998.): 725-730.

Lovett-Racke AE, Bittner P, Cross AH, Carlino JA and Racke MK. "Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).." Journal of Clinical Investigation. Vol. 101, no. 8. (January 1998.): 1797-1804.

Ratts RB, Arredondo LR, Bittner P, Perrin PJ, Lovett-Racke AE and Racke MK. "The role of CTLA-4 in tolerance induction and T cell differentiation in experimental autoimmune encephalomyelitis: i.p. antigen administration.." International Immunology. Vol. 11, no. 12. (January 1999.): 1881-8.

Ratts RB, Arredondo LR, Bittner P, Perrin PJ, Lovett-Racke AE and Racke MK. "The role of CTLA-4 in tolerance induction and antigen administration cell differentiation in experimental autoimmune encephalomyelitis: i. v. antigen administration.." International Immunology. Vol. 11, no. 12. (January 1999.): 1889-1896.

Perrin PJ, Lovett-Racke AE, Phillips SM and Racke MK. Histology and Histopathology. Vol. 14, (January 1999.): 1269-1276.

Lovett-Racke AE, Smith ME, Arredondo LR, Bittner PS, Ratts RB, Shive CL, Forsthuber TG and Racke MK. "Developmentally regulated gene expression of Th2 cytokines in the brain.." Brain Research. Vol. 870, no. 1-2. (January 2000.): 27-35.

Racke MK, Ratts RB, Arredondo L, Perrin PJ and Lovett-Racke AE. Journal of Neuroimmunology. Vol. 107, (January 2000.): 205-215.

Peters TR, Bodine DM, McDonagh KT, Lovett-Racke AE, McFarland HF, McFarlin DE, Nienhuis AW and Racke MK. "Retrovirus mediated gene transfer of the self antigen MBP into the bone marrow of B10.PL mice does not confer resistance to experimental autoimmune encephalomyelitis." Journal of Neuroimmunology. Vol. 103, (January 2000.): 51-62.

Arredondo LR, Deng C, Ratts RB, Lovett-Racke AE, Holtzman DM and Racke MK. "Role of nerve growth factor in experimental autoimmune encephalomyelitis." European Journal of Immunology. Vol. 31, no. 2. (January 2001.): 625-633.

Frohman EM, Monson NL, Lovett-Racke AE and Racke MK. Journal of Clinical Immunology. Vol. 21, (January 2001.): 61-73.

Racke MK, Lovett-Racke AE, Karandikar NJ, Wilson B and Monson NL. NeuroScience News. Vol. 4, (January 2001.): 29-38.

Lovett-Racke AE and Racke MK. "Retinoic acid promotes the development of Th2-like human myelin basic protein-reactive T cells." Cellular Immunology. Vol. 215, no. 1. (January 2002.): 54-60.

Karandikar NJ, Crawford MP; Yan X, Ratts,RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA and Racke MK. "Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis." Journal of Clinical Investigation. Vol. 109, no. 5. (January 2002.): 641-9.

Diab A, Deng C, Smith JD, Hussain RZ, Phanavanh B, Lovett-Racke AE, Drew PD and Racke MK. "Peroxisome proliferator-activated receptor-gamma agonist 12-deoxy-delta (12,14)-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis." Journal of Immunology. Vol. 168, no. 5. (January 2002.): 2508-2515.

Deng C, Minguela A, Hussain RZ, Lovett-Racke AE, Radu C, Ward ES and Racke MK. "Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis.." Journal of Immunology. Vol. 168, no. 9. (January 2002.): 4511-8.

Deng C, Wu Bo, Yang H, Hussain RZ, Lovett-Racke AE, Christadoss P and Racke MK. "Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.." Journal of neuroimmunology. Vol. 138, no. 1-2. (January 2003.): 76-82.

Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, Sikder D and Racke MK. "Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.." Immunity. Vol. 21, no. 5. (January 2004.): 719-731.

Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD and Racke MK. "Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis.." Journal of Neuroimmunology. Vol. 148, no. 1-2. (January 2004.): 116-126.

Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD and Racke MK. "Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.." Journal of Immunology. Vol. 172, no. 9. (January 2004.): 5790-5798.

Racke MK, Hu W and Lovett-Racke AE. Trends in Immunology. Vol. 26, (January 2005.): 289-291.

Muir MT, Lovett-Racke AE and Racke MK. Expert Review in Clinical Immunology. Vol. 1, (January 2005.): 345-355.

Lovett-Racke AE, Cravens PD, Gocke AR, Racke MK and Stuve O. Archives of Neurology. Vol. 62, (January 2005.): 1810-1813.

Frohman EM, Brannon K, Frohman TC, Giesser B, Langer-Gould A, Levalds C, Lovett-Racke AE, Treadaway K, Waubant E, Winslow H and Wuermser LA. "Part 2: Clinical manifestations and symptomatic treatment strategies." Female Patient. Vol. 30, (January 2005.): 46-50.

Frohman EM, Brannon K, Frohman TC, Giesser B, Langer-Gould A, Levalds C, Lovett-Racke AE, Treadaway K, Waubant E, Winslow H and Wuermser LA. "Part 1: Characterizing the disease process." Female Patient. Vol. 30, (January 2005.): 41-46.

Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA and Racke MK. "Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity.." Journal of Neuroimmunology. Vol. 172, no. 1-2. (January 2006.): 94-103.

Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ and Racke MK. "CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.." Journal of Neuroimmunology. Vol. 178, no. 1-2. (January 2006.): 117-129.

Ratts RB, Karandikar NJ, Hussain RZ, Choy J, Northrop SC, Lovett-Racke AE and Racke MK. "Phenotypic characterization of autoreactive T cells in multiple sclerosis.." Journal of Neuroimmunology. Vol. 178, no. 1-2. (January 2006.): 100-110.

Racke MK, Gocke AR, Muir M, Diab A, Drew PD and Lovett-Racke AE. "The potential of PPAR agonists to treat multiple sclerosis." Journal of Nutrition. Vol. 136, (January 2006.): 700-703.

Lovett-Racke AE and Racke MK. Archives of Neurology. Vol. 63, (January 2006.): 810-811.

Stuart R, Lovett-Racke AE, Frohman EM, Hawker K and Racke MK. "Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis.." Journal of Neuroimmunology. Vol. 191, no. 1-2. (January 2007.): 45-50.

Yang Y, Ratts RB, Hussain RZ, Northrop SC, Ben LH, Lovett-Racke A and Racke MK. "CD28:B7 interaction is necessary for the protective effect of T cell vaccination in EAE.." European Journal of Immunology. Vol. 37, no. 7. (January 2007.): 2032-2042.

Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke AE, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kiesseier BC, Racke MK, Frohman EM and Hemmer B. Archives of Neurology. Vol. 64, (January 2007.): 169-176.

Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK and Lovett-Racke AE. "T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.." Journal of Immunology. Vol. 178, no. 3. (January 2007.): 1341-1348.

Yang Y, Gocke AR, Lovett-Racke AE, Drew PD and Racke MK. PPAR Research. Vol. 2008, (January 2008.): 546753-.

Novak JC, Lovett-Racke AE and Racke MK. Archives of Neurology. Vol. 65, (January 2008.): 1162-1165.

Harp CT, Lovett-Racke AE, Racke MK, Frohman EM and Monson NL. "Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis." Clinical Immunology. Vol. 128, (January 2008.): 382-391.

Racke MK, Lovett-Racke AE and Karandikar N.J. Neurology. (January 2009.): -.

Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK and Lovett-Racke AE. "T-bet is essential for encephalitogenicity of both TH1 and TH17 cells." Journal of Experimental Medicine. Vol. 206, no. 7. (January 2009.): 1549-1564.

Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE and Racke MK. "Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-alpha agonists in autoimmune disease." Journal of Immunology. Vol. 182, (January 2009.): 4479-4487.

Racke JK, Lovett-Racke AE, Karandikar NJ.. "The mechanism of action of glatiramer acetate treatment in multiple sclerosis." Neurology. Vol. 74, no. Suppl 1. (January 2010.): S25-S30.

Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben LH, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, McTigue DM and Lovett-Racke AE. "Silencing Nogo-A promotes functional recovery in demyelinating disease." Annals of Neurology. Vol. 67, no. 4. (January 2010.): 498-507.

Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain R, Breil A, Elliott JL, Puthaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C and Stüve O. "Pharmacological PrP-silencing accelerates CNS autoimmune disease via TCR signaling." Brain. Vol. 133 (part 2), (January 2010.): 375-388.

 

Reference Works

January 1992 Lovett A, McCarthy M, Frey T, Rice C, Wolinsky JS."Rubella-specific cytotoxic T-cell responses" . : A1334
January 1998 Willenborg DO, Racke MK, Lovett-Racke AE, Hoffman LM, Karpus WJ, Owens T."Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental encephalomyelitis - Discussion" . : 843
January 1998 Lovett-Racke A, Trotter J, Lauber J, Perrin P, June C and Racke M."Decreased dependence of myelin basic protein-reative T cells on CD28-mediated costimulation in multiple sclerosis patients" . : 75
January 1998 Lovett-Racke A, Bittner P, Cross A, Carlino J and Racke M."Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF binding protein-3 complex" . : 60
January 1998 Racke MK, Trotter JL, Perrin PJ, June CH, Lovett-Racke AE."Decreased dependence of myelin basic protein-specific T cells on CD28-mediated costimulation in multiple sclerosis patients" . : A358
January 1998 Segal BM, Willenborg DO, Racke MK, Lovett-Racke AE, Hoffman LM, Karpus WJ, Begolka WS, Miller SD."Immune cell entry to the CNS - a focus for immunoregulation of EAE - Discussion" . : 844
January 1998 Begolka WS, Miller SD, Segal BM, Racke MK, Lovett-Racke AE."Antigen-driven regulation of experimental autoimmune encephalomyelitis - Discussion" . : 842
January 1998 Owens T, Segal BM, Racke MK, Lovett-Racke AE, Begolka WS, Miller SD."Tumour necrosis factor-alpha and lymphotoxin-alpha in the pathology of experimental autoimmune encephalomyelitis: is either one responsible or is there another ligand-mediated disease? Discussion" . : 849
January 2001 Deng CS, Hussain R, Lovett-Racke A, Radu C, Minguela A, Ward S, Racke M."The tyrosine phosphatase SHP-1 deficiency enhances the T cell response and exacerbates experimental autoimmune encephalomyelitis" . : A1060
January 2001 Deng C, Hussain R, Lovett-Racke AE, Rocken M and Racke MK."Monomethylfumarate induces a Th2 immune response and suppresses experimental autoimmune encephalomyelitis" . : 96
January 2001 Lovett-Racke AE, Diab A, Deng C, Hussain R, Smith J and Racke MK."Th2 cytokine expression in the developing central nervous system" . : 101
January 2001 Ratts RB, Karandikar NJ, Lovett-Racke AE, Monson NL, Smith JD and Racke MK."An increased immune response to glatiramer acetate is short lived and may not explain its long-term therapeutic benefit in treated multiple sclerosis patients" . : 137
January 2002 Ghoreschi K, Deng C, Hussain RZ, Viale O, Reitmeier C, Lovett-Racke AE, Racke MK and Rocken M."Abrogating the pathogenicity of autoreactive T cells with anti-psoriatic agents" . : 8
January 2002 Ghoreschi K, Deng C, Hussain RZ, Reitmeier C, Lovett-Racke A, Racke MK, Rocken M."Therapeutic immune deviation abrogates pathogenicity of autoreactive T cells" . : 319
January 2002 Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Lovett-Racke AE, Douek DC, Koup RA, Racke MK."Induction and restoration of CD8+ T cell responses following glatiramer acetate (Copaxone) therapy in multiple sclerosis" . : S90
January 2002 Karandikar NJ, Crawford MP, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Douek DC, Koup RA, Racke MK."Treatment with glatiramer acetate (GA) induced and restores CD8+ T-cell responses in patients with multiple sclerosis" . : A246
January 2002 Karandikar NJ, Crawford MP, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Douek DC, Koup RA, Racke MK."Treatment with glatiramer acetate (GA; Copaxone) induces and restores CD8+ T-cell responses in patients with multiple sclerosis" . : A1046
January 2004 Rocchini AE, Choy J, Northrop SC, Hussain RZ, Sikder D, Racke MK and Lovett-Racke AE."The role of T-bet in the differentiation of encephalitogenic T cells" . : 62
January 2004 Ratts R, Lovett-Racke A, Karandikar N and Racke MK."Characterization of chronically stimulated T cells in humans" . : 216
January 2004 Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ and Racke MK."Silencing T-bet prevents autoimmune demyelinating disease" . : 52
January 2004 Hansen B, Lovett-Racke AE, Hussain RZ, Northrop SC and Racke MK."The role of toll-like receptors in the pathogenesis of EAE" . : 57
January 2006 Cravens PD, Gocke AR, Northrop SC, Ben L, Hussain RZ, Racke MK and Lovett-Racke AE."The role of T-bet in the regulation of inflammation in the CNS" . : 64
January 2006 Gocke AR, Hussain RZ, Ben L, Lovett-Racke AE and Racke MK."Transcription modulation of the immune response by PPARalpha agonists ameliorates EAE" . : 164
January 2008 Yang Y, Weiner J, Liu Y, Racke M and Lovett-Racke A."Defining autoreactive encephalitogenic T cells" . : 234
January 2008 Smith AJ, Yang Y, Weiner J, Racke MK and Lovett-Racke AE."Defining the role of IL-23 in the differentiation of encephalitogenic T cells" . : 239
January 2008 Harp C, Lovett-Racke A, Racke M, Frohman E and Monson N."B-T cell interactions in multiple sclerosis" . : 139
January 2008 Lovett-Racke AE, Gocke AR, Yang Y, Hussain R, Liu Y, Ben L, Cravens P and Racke MK."Role of T-bet in regulating autoimmune Th1 and Th17 cells" . : 158
January 2009 Nessler S, Hu W, Hemmer B, Eagar T, Kane L, Leliveld R, Muller-Schiffmann A, Gocke A, Lovett-Racke A, Li-Hong B, Hussain R, Breil A, Elliott J, Carlson P, Cravens P, Singh MP, Petsch B, Stitz L, Racke M, Korth C, Stuve O."Prion protein is a key regulator of T-cell activation, differentiation and survival" . : S192
January 2009 Hu W, Nessler S, Hemmer B, Eagar T, Kane L, Leliveld R, Muller-Schiffmann A, Gocke A, Lovett-Racke A, Ben LH, Hussain R, Breil A, Elliott J, Carson P, Cravens P, Singh M, Petsch B, Stitz L, Racke M, Korth C, Stuve O."Prior Protein is a key regulator of T cell activation, differentiation and survival" . : A280
January 2009 Racke M, Yang Y, Liu Y, Smith A, Winger R, Peng H, Cravens P, Lovett-Racke A."T-bet, not cytokine expression, determines T-cell encephalitogenicity" . : S59

Presentations

"Immune Mechanisms and Autoimmune Injury." Presented at Neurology Residence Conference, Dallas, TX. (January 2003)

"Immune Deviation as a Potential Therapy for Multiple Sclerosis." Presented at Rheumatology Seminar, Dallas, TX. (January 2003)

"Silencing T-bet prevents autoimmune demyelinating disease." Presented at 7th Congress of the International Society for Neuroimmunology, Venice, IT|ITA. (January 2004)

"Immune Mechanisms and Autoimmune Injury." Presented at Neurology Residence Conference, Dallas, TX. (January 2004)

"Therapeutic Potential of Gene Silencing in Immune-mediated Demyelinating Disease." Presented at Neurology Grand Rounds, Dallas, TX. (January 2004)

"Therapeutic benefit of silencing T-bet in autoimmune demyelinating disease." Bethesda, MD. (May 2005)

"Development of New Therapeutic Agents for Multiple Sclerosis." Presented at UT Southwestern Medical Center, Dallas, TX. (January 2005)

"Therapeutic potential of siRNA for multiple sclerosis." Columbus, OH. (April 2005)

"Therapeutic potential of siRNA for the treatment of multiple sclerosis." Presented at Consortium of Multiple Sclerosis Center Annual Meeting, Orlando, FL. (June 2005)

"T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity." Presented at Americas Committee for the Treatment and Research in Multiple Sclerosis Meeting, Chicago, IL. (October 2006)

"Therapeutic potential of siRNA for multiple sclerosis." Presented at 8th Annual Frontiers in Neuroscience Research Day, Charleston, SC. (March 2007)

"Identifying Therapeutic Targets for Multiple Sclerosis." Presented at OSU Molecular Virology, Immunology and Medical Genetics Seminar, Columbus, OH. (February 2008)

"Role of T-bet in Autoreactive Th1 and Th17 Cells." Presented at Ohio State University Immunology Seminar, Columbus, OH. (May 2008)

"Silencing T-bet Suppresses Th1 and Th17 Cell Differentiation." Presented at Experimental Biology 2008, San Diego, CA. (April 2008)

"Role of T-bet in Regulating Autoimmune Th1 and Th1 Cells." Presented at Congress of the International Society for Neuroimmunology, Fort Worth, TX. (October 2008)

"Defining the Role of T-bet in Encephalitogenic Th1 and Th17 Cells." Presented at Tykeson Fellows Conference on Multiple Sclerosis, Chicago, IL. (November 2008)

"T-bet or not T-bet, that is the question (in autoimmunity)." Presented at OSU Molecular Virology, Immunology & Medical Genetics Seminar, Columbus, OH. (November 2009)

 

Professional Activities

2008 - present Pilot Project. National Multiple Sclerosis Society.
2009 - present Challenge Grants. National Institutes of Neurological Disorders and Stroke.
2009 - present National Multiple Sclerosis Society.
2004 Pilot Project. National Multiple Sclerosis Society.
2005 Pilot Project. National Multiple Sclerosis Society.
2005 Ad-hoc. Medical Research Council.
2006 Clinical Neuroimmunology and Brain Tumor Study Section Ad-hoc. National Institutes of Neurological Disorders and Stroke.
2007 Pilot Project. National Multiple Sclerosis Society.